Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: PR Newswire
SOUTH SAN FRANCISCO, Calif., May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board. Dr. Paya is a proven academic and industry leader with 30 years of experience in leadership roles. For the past 9 years he has served as President and CEO at Immune Design Corp., (acquired by Merck). Prior to that he held leadership positions at Elan and Eli Lilly and was a Professor of Medicine and Immunology at the Mayo Clinic for 10 years. Dr. Paya received his M.D. and Ph.D. degree from the University Complutense of Madrid in Spain."Sutro is entering an important phase of growth as it moves multiple product candidates thro
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors [Seeking Alpha]Seeking Alpha
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $12.00.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
STRO
Earnings
- 11/13/23 - Miss
STRO
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/26/24 - Form DEFA14A
- STRO's page on the SEC website